Accelerating Cancer Therapeutics (ACT)

Accelerating Cancer Therapeutics (ACT) is an accelerator program designed to leverage Columbia’s proficiency in drug discovery and provide access to entrepreneurs and the pharmaceutical industry to advance novel cancer therapeutics from the lab towards the path of commercialization and clinical implementation. The program will provide education, mentorship and funding to help academic translational research projects move beyond the “valley of death” in therapeutic development and reach significant milestones. A key goal of this program is to accelerate translation of novel medical discoveries in cancer from the lab to the clinic by positioning the technology for commercialization. Researchers are also encouraged to submit their funded research outcomes for publication in academic journals, as usual.


Cumulative Success Metrics

  • 5 cycles administered
  • 59 applications received
  • 53 teams accepted
  • 20 teams that received funding
  • Over $1M in funding awarded by ACT to teams
  • $5M in funding awarded to teams by external sources